Delving into the Latest Updates on Tirzepatide with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Tirzepatide (USAN), TZP, ZEHP-bownd

+ [16]

Target

GIPR x GLP-1R

Action

agonists

Mechanism

GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseRespiratory Diseases+ [9]

Active Indication

Obesity Hypoventilation SyndromeSleep Apnea, ObstructiveObesity+ [15]

Inactive Indication

HypoglycemiaKidney Failure, ChronicLiver Injury+ [2]

Originator Organization

Lexaria Bioscience Corp.

Eli Lilly & Co.

Active Organization

Eli Lilly & Co.

Lilly Asia Shanghai Representative OfficeEli Lilly Japan KK

+ [9]

Inactive Organization-

License Organization

Eli Lilly Japan KK

Eli Lilly & Co.

Tanabe Pharma Corp.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (13 May 2022),

Diabetes Mellitus, Type 2

RegulationPriority Review (United States), Priority Review (China), Breakthrough Therapy (China), Fast Track (United States)

Login to view timeline

Structure/Sequence

Sequence Code 10195070

Source: *****

This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

Start Date01 Dec 2026

Sponsor / Collaborator

Royal North Shore Hospital

NCT07468552

/ Not yet recruitingPhase 2IIT

Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)

The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.

Start Date15 Nov 2026

Sponsor / Collaborator

National Institute on Drug Abuse

100 Clinical Results associated with Tirzepatide

Login to view more data

100 Translational Medicine associated with Tirzepatide

Login to view more data

100 Patents (Medical) associated with Tirzepatide

Login to view more data

1,704

Literatures (Medical) associated with Tirzepatide

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK

Article

Author: Kanumilli, Naresh ; Evans, Jerome ; Cattin, Juliette ; Debackere, Nele ; Osumili, Beatrice ; Buckingham, Mike ; Hunt, Barnaby ; Webb, Joanne ; Nowakowski, Piotr

INTRODUCTION:

Tirzepatide is a treatment for type 2 diabetes associated with improvements in glycemic control and weight loss, and a low risk of hypoglycemia when not used in combination with insulin or insulin secretagogues. A cost to target analysis of tirzepatide 5, 10 and 15 mg versus subcutaneous semaglutide 1 mg in the UK setting was performed, calculating the annual pharmacy cost per patient treated to six composite endpoints combining glycemic control (glycated hemoglobin [HbA1c] ≤ 6.5% [48 mmol/mol] and <7.0% [53 mmol/mol]) with weight loss (≥5%, ≥10%, ≥15%) and avoidance of hypoglycemia. The costing analysis was based on the tirzepatide costs appraised by NICE as part of TA924.

METHODS:

The proportions of patients achieving composite treatment targets with tirzepatide and semaglutide (both in combination with metformin) were taken from a post-hoc analysis of the SURPASS-2 clinical trial (N = 1,845). Costs per patient treated to target were calculated by dividing the annual treatment costs associated with each intervention by the proportion of patients achieving the treatment target with each intervention.

RESULTS:

Tirzepatide 5, 10 and 15 mg were associated with a lower pharmacy cost per patient achieving treatment target than semaglutide 1 mg for the majority of endpoints evaluated. Differences became greater at more strict treatment targets. For example, the cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650, GBP 8,665 and GBP 9,462 lower with tirzepatide 5, 10 and 15 mg, respectively, compared with semaglutide 1 mg over a 1-year time horizon. The only endpoint where semaglutide 1 mg was associated with a lower cost per patient achieving target was HbA1c <7.0%, weight loss ≥5%, and no hypoglycemia.

CONCLUSIONS:

Compared to semaglutide, tirzepatide was associated with a lower annual pharmacy cost per patient with diabetes achieving treatment target in the UK for the majority of endpoints, with greater differences at more strict treatment targets.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation

Article

Author: Yao, Tie-Feng ; Sun, Lu ; Yu, Sheng-Xue ; Yu, Hong-Dan ; Yao, Su-Yan ; Zuo, Zhong-Fu ; Lu, Si-Jing ; Hou, Yang ; Zheng, Han-Song ; Sun, Qing-Lin

01 Jun 2026·Addictive behaviors reports

Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov

Article

Author: Jha, Nandini ; Jha, Manish K ; Patil, Shruti

Background:

Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for several SUDs (such as methamphetamine, cocaine, and cannabis use disorders). Emerging evidence suggests glucagon-like peptide 1 receptor agonists (GLP-1RAs) may improve outcomes related to SUD. Therefore, a systematic survey of ongoing clinical trials that are evaluating the effects of GLP-1RAs for SUDs is warranted.

Methods:

We searched ClinicalTrials.gov from inception to July 2, 2025 (preregistered at: https://osf.io/x58ne/). Inclusion required a GLP-1RA intervention targeting SUDs and outcomes regarding substance use (e.g., urine toxicology, Timeline Follow-Back, craving). Trials excluding individuals with SUDs were excluded.

Results:

Of 192 records, 33 met criteria: alcohol use disorder (n = 15), nicotine/tobacco (n = 9), cocaine (n = 4), opioid (n = 4), methamphetamine (n = 1), and none for cannabis. Agents studied included semaglutide (n = 15), exenatide (n = 8), tirzepatide (n = 6), liraglutide (n = 2), dulaglutide (n = 1), and pemvidutide (n = 1). Outcomes and designs were heterogeneous and often mixed self-report with objective indices. Most studies used older GLP-1RAs, focused mainly on alcohol or nicotine/tobacco use disorder, and used a range of outcome measures relying on self-reported and objective measures of substance use.

Conclusions:

While GLP-1RAs may represent a paradigm shift for treating SUD, current trials have focused on alcohol and nicotine/tobacco use disorders, with notable gaps for methamphetamine and cannabis use disorders. Trials testing next-generation GLP-1RAs with FDA recommended endpoints are needed to define efficacy and safety across SUDs.

1,759

News (Medical) associated with Tirzepatide

17 Apr 2026

·www.prnewswire.com

Annals of Internal Medicine presents breaking scientific news at ACP's Internal Medicine Meeting 2026

Authors discuss evidence-based research on mammography screening, AI in medicine, and obesity medications and body composition SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- Today at ACP's annual meeting, Internal Medicine Meeting 2026, Annals of Internal Medicine presented three breaking research articles during a live scientific plenary session that featured the authors of those articles. The articles were published in ACP's flagship journal concurrently with the live meeting presentation. During the session, New in Annals of Internal Medicine: Hear it First from the Authors, researchers presented their work to meeting attendees and provided insight into ACP's guidance statement on mammography screening for breast cancer, the use of AI for medical documentation, and the effect of weight loss medications on body composition. Continue Reading Christine Laine, MD, MPH, Editor of Annals of Internal Medicine, discusses scientific plenary topics with the study authors. Christine Laine, M.D., MPH, Annals of Internal Medicine Editor-in-Chief and ACP Senior Vice President, introduced the authors and facilitated a discussion on each topic. The articles and presentations included: Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement from the American College of Physicians. Carolyn Crandall, M.D. Professor of Medicine at the David Geffen School of Medicine at UCLA and Chair of ACP's Clinical Guidelines Committee, provided context and rationale for the advice detailed in ACP's new mammography screening guidance statement. Dr. Crandall explained that women at average risk between the ages of 50 and 74 should undergo biennial mammography screening for breast cancer. Females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the benefits and harms of screening, such as false positive results, psychological distress because of it, overdiagnosis, overtreatment, additional testing, and radiation exposure before making a shared decision about screening. ACP also provided advice for women with dense breasts, Dr. Crandall explained. ACP suggests doctors consider supplemental digital breast tomosynthesis in this population, advising against using supplemental MRI or ultrasound. Decisions should consider potential benefits and harms, radiation exposure, availability, patient values and preferences, and costs. Dr. Crandall noted that ACP's guidance is based on a systematic review of the best-available evidence, taking into consideration important population-related benefits and harms. Documentation of Artificial Intelligence–Generated and Human-Produced Clinical Notes Ashok Reddy, MD, MSc, Associate Director of the VA Primary Care Analytics Team for the Veterans Health Administration, Deputy Section Head for the VA Puget Sound, and Associate Professor of Medicine at the University of Washington, discussed findings of a study comparing the quality of doctors' notes generated by ambient AI scribe tools or those written by human clinicians. The researchers compared recordings of five standardized primary care visits and asked 11 AI scribe tools and 18 human clinicians to generate clinical notes from them. In every case and by every measure, human notes scored better than AI notes for accuracy, thoroughness, usefulness, organization, and comprehensiveness. Dr. Reddy explained that while AI scribe tools may reduce administrative burden, they should be regarded as a tool for generating draft documentation that requires careful review and editing. He warned that AI is currently no substitute for clinician-authored notes. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition John A. Batsis M.D., Associate Professor, Division of Geriatric Medicine and the Department of Nutrition at the University of North Carolina, Chapel Hill, explained how incretin-based medications affect body composition. Dr. Batsis and colleagues reviewed 36 randomized controlled trials reporting on body composition outcomes among adults with overweight or obesity taking liraglutide, semaglutide, tirzepatide, or dulaglutide compared with nonpharmacologic interventions or placebo. They found that while the medications reduced total weight, body fat, and visceral fat, the proportion of weight lost from muscle-related tissue was concerning. Dr. Batsis noted that half of the placebo/lifestyle interventions examined also exceeded prespecified benchmarks for muscle-related loss, despite these interventions often leading to more modest weight loss. The researchers stress the need for clinicians to proactively counsel patients around muscle-related losses associated with weight reduction and muscle-preserving strategies to incorporate alongside pharmacotherapy. "The Annals scientific plenary session has become a vital forum for showcasing practice changing research at ACP's Internal Medicine Meeting, and attendees should leave knowing they have new information– that will help them provide the best possible patient care. The studies featured this year once again reflect the rigor, curiosity, and clinical relevance that Annals readers and ACP members consistently expect," said Dr. Laine. About the American College of Physicians The American College of Physicians is the largest medical specialty organization in the United States with members in more than 172 countries worldwide. ACP membership includes 163,000 internal medicine physicians, related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on X, Facebook, Instagram, Threads, and LinkedIn, and subscribe to our RSS feed. About Annals of Internal Medicine Annals of Internal Medicine is the flagship journal of the American College of Physicians (ACP). Annals is the most cited general internal medicine journal and one of the most influential peer-reviewed clinical journals in the world. Annals' mission is to promote excellence in medicine, enable physicians and other health care professionals to be well-informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. New content is published every Tuesday at Annals.org. Follow Annals on X, Instagram, LinkedIn, Bluesky, and on Facebook. SOURCE American College of Physicians 21% more press release views with Request a Demo

17 Apr 2026

·endpoints.news

Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests

While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as a preprint , spotlights the fierce competition between Lilly and Novo in the weight loss drug market. Both companies have been trying to edge the other out by showcasing value-added drug features as well as investing in next-generation approaches and advancing oral formulations . In a longitudinal analysis, patients taking tirzepatide lost an average 15.2% of their total body weight at one year, compared with 9.7% for semaglutide patients, according to the Massachusetts-based data analytics company nference. But those receiving Lilly’s drug also lost about 5.6% of their lean body mass at one year, compared with 3.6% loss for Novo’s medicine. The average loss in lean body mass was numerically higher for tirzepatide at the three-, six-, and nine-month time points as well. The analysis looked at data from around 1,800 tirzepatide patients and 6,200 semaglutide patients. Endpoints News has reached out to Lilly and Novo for comment. Muscle mass plays an important role in maintaining weight loss over the long term because muscle tissue burns more calories than fat when a person is at rest. Companies that are yet to enter the market, like Scholar Rock and Regeneron , are working on weight loss approaches that they say could help preserve lean body mass. These approaches involve combining GLP-1 drugs with candidates that inhibit myostatin, a protein that limits muscle growth. Lilly is also testing a myostatin inhibitor called bimagrumab in combination with Wegovy . Bimagrumab was originally developed by Novartis. As for Wave Life Sciences’ closely-watched WVE-007, it maintained lean mass in a Phase 1 trial but its weight loss data underwhelmed . Also this week, research in mice with fatty liver disease showed that certain liver cells carry receptors for semaglutide, and the drug stimulates those cells to release compounds with an anti-inflammatory effect in the liver. Wegovy secured FDA approval for MASH last year, and tirzepatide has Phase 2 data in the indication. A separate group of researchers designed a candidate that targets only GIP and glucagon, without acting on GLP-1. In monkey and rodent studies , the drug induced weight loss comparable to that seen with GLP-1 targeting drugs, without the usual gastrointestinal side effects, the researchers said. Earlier this week, the FDA asked Lilly for more cardiovascular event and liver damage data in its approval letter for Foundayo. In a Phase 3 trial looking at Foundayo’s ability to reduce cardiovascular events, the drug showed no signs of liver toxicity . Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.

Clinical ResultPhase 1Phase 2Phase 3

17 Apr 2026

·firstwordpharma.com

Zepbound leads to greater weight loss — and muscle loss — than Wegovy: study

With Eli Lilly and Novo Nordisk locked in a heated contest for obesity supremacy, every data point counts as they vie for prescription share (see – Vital Signs: Eli Lilly takes no prisoners in obesity battle and Vital Signs: How GLP-1s are defining the growth profile of major pharma).Now, a preprint published this week in medRxiv has shed more light on how their respective injectable weight-loss drugs affect body composition, and the findings could sway more physicians towards the Danish drugmaker's GLP-1 agonist, if preserving muscle is a key priority for patients. Researchers from the Metabolism Agentic Intelligence Atlas (MAIA) in Cambridge, Mass. conducted a longitudinal analysis of 7965 individuals taking either Novo's Wegovy (semaglutide) or Lilly's GLP-1/GIP dual agonist Zepbound (tirzepatide) who had both pre-treatment and post-initiation body-composition measurements taken over the course of a year.Consistent with clinical data, Zepbound boasted the greatest weight loss, with patients losing an average 15.2% of their bodyweight at the 12-month mark; patients taking Wegovy shed about 9.7% of their weight at the same time point. However, Zepbound also led to a 2% greater decrease in lean body mass (LBM). After one year, patients on Lilly's drug lost about 3.3 kg of their LBM, for a 5.6% decrease, while Wegovy was linked to an LBM loss of 2.3 kg, or a 3.6% total decline. "Although tirzepatide delivers superior weight reduction compared with semaglutide, the accompanying increase in LBM loss suggests that more potent energy deficit induction may come at the cost of greater muscle catabolism, potentially mediated by higher degrees of caloric restriction, altered protein turnover, or differential GIP and GLP-1 signalling effects," the authors wrote.The team also found that a greater degree of LBM loss was functionally correlated with reduced exercise tolerance, with the signal appearing "more prominently" with Zepbound than with Wegovy. The finding "may be particularly salient to continue monitoring given the greater absolute LBM loss associated with tirzepatide treatment relative to semaglutide treatment," the authors wrote. However, they do note that the association between total weight loss and LBM loss is a "weak coupling," which could be a positive in the long run for newcomers to the weight-loss space specifically targeting muscle preservation. If the two processes "are at least partially biologically dissociable," the authors argue, then "muscle preserving weight loss is an achievable therapeutic goal rather than an inherent trade off."For a look at the various tactics drugmakers are taking to stave off muscle loss, see Spotlight On: New muscle-preserving therapies emerge as GLP-1 use grows.

Clinical Result

100 Deals associated with Tirzepatide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Obesity Hypoventilation Syndrome	China	Eli Lilly Suzhou Pharmaceutical Co. Ltd.	30 Jun 2025
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Reduced ejection fraction co-occurrent and due to chronic heart failure	NDA/BLA	European Union	Eli Lilly & Co.	-
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United States	Eli Lilly & Co.	23 Dec 2025
Metabolic dysfunction-associated steatotic liver disease	Phase 3	China	Eli Lilly & Co.	23 Dec 2025
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Bulgaria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	26 Jun 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04657016 \| NCT04660643 \| NCT04184622 (SURMOUNT-1, Pubmed \| Obes Pillars)	Phase 3	Obesity	4,726	Tirzepatide	eduvfeazqu(mvxdzqralz) = nvsuhtjzdg rqisoqvvrd (vpbvcsnzqq ) View more	Positive	01 Mar 2026
				Placebo	jigwajnyhg(vuxjpnxwcl) = iiiybyyiob xpsvspbfnt (dhzcllnyme ) View more
NCT06588283 (TOGETHER-PsO, Company_Website) Manual	Phase 3	Psoriasis \| Overweight \| Obesity	274	Taltz + Zepbound	iulbyvmreg(innpucbjtc) = dhplizvdlj dflhpdlclj (vcrswdxbfh ) Met View more	Positive	18 Feb 2026
				Taltz	iulbyvmreg(innpucbjtc) = vcnfdpvgdl dflhpdlclj (vcrswdxbfh ) Met View more
NCT04184622 (SURMOUNT-1, Pubmed \| Obesity (Silver Spring))	Phase 3	Obesity	102	Tirzepatide 5 mg	fabrplhrsk(qvgdqreddd) = zkgrwxpjxr dwmcliinda (nhrakpwxcy )	Positive	30 Jan 2026
				Tirzepatide 10 mg	fabrplhrsk(qvgdqreddd) = gktlsrgrsw dwmcliinda (nhrakpwxcy )
NCT06588296 (TOGETHER-PsA, Company_Website) Manual	Phase 3	Arthritis, Psoriatic \| Overweight \| Obesity	271	Taltz (ixekizumab) + Zepbound (tirzepatide)	tsfhlaexrj(qhubcfqsef) = rkmjxmyxot pbetzdjssd (hyhhitjdbq ) Met View more	Superior	08 Jan 2026
				Taltz (ixekizumab)	tsfhlaexrj(qhubcfqsef) = kwhyzrpoed pbetzdjssd (hyhhitjdbq ) Met View more
NCT04255433 (SURPASS-CVOT, Pubmed \| N Engl J Med)	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,174	Tirzepatide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)	fwnxffsacg(unvpzrmrfl) = The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group. szvlyfusqt (oljucnkzmn ) View more	-	18 Dec 2025
				Dulaglutide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)
NCT05822830 (SURMOUNT-5, CTgov)	Phase 3	Obesity	751	Tirzepatide (15 mg or MTD - Tirzepatide)	xmezsnnopr(krquiyptmv) = wkyavqgkgt khzqeolpxb (urkpoetcjh, 0.59) View more	-	26 Nov 2025
				Semaglutide (2.4 mg or MTD - Semaglutide)	xmezsnnopr(krquiyptmv) = peajecikrq khzqeolpxb (urkpoetcjh, 0.59) View more
NCT04657016 \| NCT04660643 \| NCT04184622 (SURMOUNT-1, Pubmed \| Obesity (Silver Spring))	Phase 3	Obesity	2,788	Tirzepatide	rwmvbqrsdt(xlelmvrzsd) = yhtjsxczdg orobapaijb (laqmbipbia ) View more	Positive	04 Nov 2025
NCT04657003 \| NCT04184622 \| NCT05536804 (SURMOUNT-1, Pubmed \| J Am Soc Nephrol)	Not Applicable	-	3,477	Tirzepatide	hukhuhbejc(dibdssmgsn): Difference (%) = −55.2 (95.0% CI, −68.5 - −36.4) View more	Positive	01 Nov 2025
				Placebo
ACR2025	Not Applicable	Overweight \| Obesity	62,722	Tirzepatide	yuiolvladh(rydkhkwjug): HR = 0.88 (95.0% CI, 0.81 - 0.95) View more	Positive	24 Oct 2025
				Phentermine
NCT05963022 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	206	Tirzepatide (10 mg Tirzepatide)	jyhfsrxvze(guwlpthoua) = rkdxyywgie ppgumdnmet (gatlzllzbq, 0.131) View more	-	21 Oct 2025
				Tirzepatide (15 mg Tirzepatide)	jyhfsrxvze(guwlpthoua) = amhbjlsnqs ppgumdnmet (gatlzllzbq, 0.124) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Tirzepatide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation